Results 211 to 220 of about 515,448 (335)

Nanogel‐Mediated Immunotherapy to Tackle Cancer and Inflammatory Diseases

open access: yesChemistryEurope, EarlyView.
Nanogels formed through self‐assembly, microemulsion, or precipitation polymerization method enable precise delivery of immunotherapeutic factors and immune cell targeting, thus effectively modulating immune responses. This review highlights recent advances in stimuli‐responsive nanogel design, underlying mechanisms, and their potentials to tackle ...
Ziwen Zhang   +7 more
wiley   +1 more source

Influence of commonly used pharmaceutical agents on equine bone marrow-derived mesenchymal stem cell viability [PDF]

open access: yes, 2017
Ankrum   +32 more
core   +2 more sources

Evaluation of the Therapeutic Potential of Bioactive Materials Based on a Complex of Oxidovanadium(IV) and Exopolysaccharide Levan in a Model of Insulin Resistance in Mice

open access: yesChemMedChem, EarlyView.
A low‐toxicity bioactive composition of oxidovanadium(IV) and exopolysaccharide levan is synthesized, characterized, and shown to reduce hyperglycemia, hypertriglyceridemia, and TyG index in a mice model of dexamethasone‐induced insulin resistance. Bioactive compositions containing vanadium complexes have been a viable strategy for constructing more ...
Amanda K. J. P. F. da Silva   +8 more
wiley   +1 more source

The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Polypharmacy is increasingly recognized as a relevant issue in diabetes care, but its prevalence and clinical relevance in individuals with type 1 diabetes remain underexplored. This study aimed to determine the prevalence of polypharmacy and to identify associated clinical and psychological factors. Participants were recruited from a tertiary diabetes
Namam Ali   +4 more
wiley   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy